Table 2.
Results of subgroup analysis of pooled hazard ratios of OS of patients with different SII
| Stratified analysis | No. of studies | Pooled HR (95% CI) | P‐value | Heterogeneity | |
|---|---|---|---|---|---|
| I2 (%) | PQ | ||||
| Cancer type | |||||
| RCC | 7 | 2.73 (1.28, 5.81) | 0.009 | 99 | < 0.001 |
| PC | 3 | 2.29 (1.44, 3.63) | < 0.001 | 46 | 0.160 |
| BC | 2 | 3.01 (1.35, 6.68) | 0.007 | 0 | 0.870 |
| Unclear | 2 | 1.92 (1.46, 2.54) | < 0.001 | 0 | 0.660 |
| Urothelial cancer | 4 | 2.03 (1.55, 2.63) | < 0.001 | 0 | 0.730 |
| Non urothelial cancer | 10 | 2.67 (1.46, 4.88) | 0.001 | 98 | < 0.001 |
| Study type | |||||
| Prospective | 1 | 2.99 (2.07, 4.32) | < 0.001 | NA | NA |
| Retrospective | 13 | 2.55 (1.53, 4.27) | < 0.001 | 97 | < 0.001 |
| Treatment | |||||
| Surgery | 5 | 1.70 (1.04, 2.79) | 0.030 | 76 | 0.002 |
| Non surgery | 7 | 2.16 (1.74, 2.68) | < 0.001 | 52 | 0.050 |
| Mix | 2 | 6.67 (1.40, 31.84) | 0.020 | 98 | < 0.001 |
| Cut-off value | |||||
| 0–500 | 2 | 9.05 (2.99, 27.41) | < 0.001 | 82 | 0.020 |
| 501–1000 | 9 | 1.84 (1.30, 2.59) | < 0.001 | 90 | < 0.001 |
| >1000 | 2 | 3.23 (2.38, 4.39) | < 0.001 | 0 | 0.450 |
| Analysis | |||||
| Multivariate | 10 | 2.06 (1.44, 2.94) | < 0.001 | 9.1 | < 0.001 |
| Univariate | 1 | 2.36 (1.78, 3.13) | < 0.001 | NA | NA |
CI: confidence interval; HR: hazard ratio; OS: overall survival; SII: systemic immune‐inflammation index